{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:24:22Z","timestamp":1764937462281,"version":"3.37.3"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.rmed.2022.106993","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T17:29:54Z","timestamp":1663781394000},"page":"106993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of inhaled fluticasone propionate\/salmeterol on health-related quality of life in asthma: A network meta-analysis"],"prefix":"10.1016","volume":"203","author":[{"given":"Kittipong","family":"Maneechotesuwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro G.","family":"Fritscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nese","family":"Dursunoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijith","family":"P.G.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"Phansalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumika","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Pizzichini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Chorazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Global Initiative for Asthma","key":"10.1016\/j.rmed.2022.106993_bib1"},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41533-017-0014-1","article-title":"The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting \u03b22-agonists in the United Kingdom: a cross-sectional analysis","volume":"27","author":"Pavord","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.rmed.2022.106993_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/npjpcrm.2014.9","article-title":"Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey","volume":"24","author":"Price","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.rmed.2022.106993_bib4","article-title":"Failure in asthma control: reasons and consequences","volume":"2013","author":"Braido","year":"2013","journal-title":"Sci. Tech. Rep."},{"issue":"6","key":"10.1016\/j.rmed.2022.106993_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/02770903.2020.1728767","article-title":"Treatment patterns among non-active users of maintenance asthma medication in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink","volume":"58","author":"Gibbons","year":"2021","journal-title":"J. Asthma"},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13223-021-00598-3","article-title":"Epidemiology of comorbidities and their association with asthma control","volume":"17","author":"Tomisa","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2022.106993_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4104\/pcrj.2013.00091","article-title":"Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK","volume":"22","author":"Fletcher","year":"2013","journal-title":"Prim. Care Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/ACI.0b013e32835c16b6","article-title":"Asthma and comorbidities","volume":"13","author":"Ledford","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2022.106993_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expet Rev. Respir. Med."},{"issue":"136","key":"10.1016\/j.rmed.2022.106993_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/16000617.00001615","article-title":"Control of asthma in real life: still a valuable goal?","volume":"24","author":"Papaioannou","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2022.106993_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/PPA.S303841","article-title":"Therapeutic inertia in prescribing biologics for patients with moderate-to-severe asthma: workshop summary","volume":"15","author":"Sico","year":"2021","journal-title":"Patient Prefer. Adherence"},{"issue":"6","key":"10.1016\/j.rmed.2022.106993_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/S1806-37132011000600002","article-title":"Asthma control and quality of life in patients with moderate or severe asthma","volume":"37","author":"Pereira","year":"2011","journal-title":"J. Bras. Pneumol."},{"issue":"2","key":"10.1016\/j.rmed.2022.106993_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaci.2007.04.040","article-title":"Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease","volume":"120","author":"Chen","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.rmed.2022.106993_bib14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.rmed.2006.03.031","article-title":"Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment","volume":"100","author":"Peters","year":"2006","journal-title":"Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2022.106993_bib15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201901-0016OC","article-title":"The projected economic and health burden of uncontrolled asthma in the United States","volume":"200","author":"Yaghoubi","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2022.106993_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2466-13-15","article-title":"The association between asthma control, health care costs, and quality of life in France and Spain","volume":"13","author":"Doz","year":"2013","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2022.106993_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1183\/09059180.06.00009801","article-title":"Cost of scheduled and unscheduled asthma management in seven European Union countries","volume":"98","author":"Williams","year":"2006","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2022.106993_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1183\/09059180.06.00009802","article-title":"On behalf of the asthma insights and reality in Asia Pacific steering committee. Cost of asthma in the Asia-Pacific region","volume":"98","author":"Lai","year":"2006","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"Reddel","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2022.106993_bib20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/all.12415","article-title":"The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use","volume":"69","author":"Barnes","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2022.106993_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1164\/ajrccm.157.1.9703002","article-title":"Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma","volume":"157","author":"Crimi","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2022.106993_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0091-6749(99)70496-3","article-title":"Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis","volume":"103","author":"Rosi","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"year":"2019","series-title":"British Guideline on the Management of Asthma","key":"10.1016\/j.rmed.2022.106993_bib23"},{"key":"10.1016\/j.rmed.2022.106993_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/JAA.S180657","article-title":"Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR): physician beliefs and practices about diagnosis, assessment, and treatment of coexistent disease","volume":"11","author":"Aggarwal","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2022.106993_bib25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.106993_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2022.106993_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/thx.47.2.76","article-title":"Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials","volume":"47","author":"Juniper","year":"1992","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0022-3999(91)90011-C","article-title":"A scale for assessing quality of life in adult asthma sufferers","volume":"35","author":"Hyland","year":"1991","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.rmed.2022.106993_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41533-019-0149-3","article-title":"A systematic review of psychological, physical health factors, and quality of life in adult asthma","volume":"29","author":"Stanescu","year":"2019","journal-title":"npj Prim. Care Respir Med."},{"issue":"S2","key":"10.1016\/j.rmed.2022.106993_bib30","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.5694\/mja18.00207","article-title":"Health-related quality of life burden in severe asthma","volume":"209","author":"McDonald","year":"2018","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.rmed.2022.106993_bib31","first-page":"1012","article-title":"Health related quality of life in asthma: a systematic review","volume":"2","author":"Malik","year":"2017","journal-title":"Arch Palliat Care"},{"issue":"4","key":"10.1016\/j.rmed.2022.106993_bib32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jaci.2015.03.023","article-title":"Magnitude of effect of asthma treatments on asthma quality of life questionnaire and asthma control questionnaire scores: systematic review and network meta-analysis","volume":"136","author":"Bateman","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib33","article-title":"Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma","volume":"7","author":"Lee","year":"2020","journal-title":"BMJ Open Respir Res."},{"key":"10.1016\/j.rmed.2022.106993_bib34","first-page":"CD005533","article-title":"Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma","volume":"4","author":"Ducharme","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2022.106993_bib35","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1067\/mai.2000.105711","article-title":"Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial","volume":"105","author":"Kavuru","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2022.106993_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/ajrccm.161.2.9905091","article-title":"Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma","volume":"161","author":"Shapiro","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.rmed.2022.106993_bib37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2022.106993_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1183\/09031936.00128505","article-title":"The correlation between asthma control and health status: the GOAL study","volume":"29","author":"Bateman","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.106993_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2022.106993_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1378\/chest.115.5.1265","article-title":"Validation of a standardised version of the asthma quality of life questionnaire","volume":"115","author":"Juniper","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2022.106993_bib42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2022.106993_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific quality of life instrument","volume":"47","author":"Juniper","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2022.106993_bib45","first-page":"1107","article-title":"The GRACE checklist: a validated assessment tool for high quality observational studies of comparative effectiveness","volume":"22","author":"Dreyer","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.rmed.2022.106993_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.rmed.2022.106993_bib47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"year":"2022","article-title":"Cochrane handbook for systematic reviews of interventions version 6.3 (updated february 2022). Cochrane","key":"10.1016\/j.rmed.2022.106993_bib48"},{"issue":"3\u20134","key":"10.1016\/j.rmed.2022.106993_bib49","first-page":"50","article-title":"Salmeterol\/fluticasone propionate (50\/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma","volume":"134","author":"Bergmann","year":"2004","journal-title":"Swiss Med. Wkly."},{"author":"gov","key":"10.1016\/j.rmed.2022.106993_bib50"},{"key":"10.1016\/j.rmed.2022.106993_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1465-9921-8-46","article-title":"Salmeterol\/fluticasone stable-dose treatment compared with formoterol\/budesonide adjustable maintenance dosing: impact on health-related quality of life","volume":"8","author":"Price","year":"2007","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2022.106993_bib52","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1742-1241.2007.01338.x","article-title":"Effect of budesonide\/formoterol maintenance and reliever therapy on asthma exacerbations","volume":"61","author":"Kuna","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.rmed.2022.106993_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/11533450-000000000-00000","article-title":"Treatment comparison of budesonide\/formoterol with salmeterol\/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study","volume":"30","author":"Kuna","year":"2010","journal-title":"Clin. Drug Invest."},{"issue":"5","key":"10.1016\/j.rmed.2022.106993_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/09031936.05.00028305","article-title":"Budesonide\/formoterol maintenance and reliever therapy: an effective asthma treatment option?","volume":"26","author":"Vogelmeier","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2022.106993_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/02770903.2017.1350971","article-title":"Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate\/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older","volume":"55","author":"Raphael","year":"2018","journal-title":"J. Asthma"},{"issue":"8","key":"10.1016\/j.rmed.2022.106993_bib56","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.rmed.2010.04.003","article-title":"Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist","volume":"104","author":"Reddel","year":"2010","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2022.106993_bib57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF03257170","article-title":"Impact of inhaled salmeterol\/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma","volume":"1","author":"Juniper","year":"2002","journal-title":"Am. J. Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2022.106993_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1081-1206(10)60338-9","article-title":"Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life","volume":"102","author":"Edin","year":"2009","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2022.106993_bib59","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2500\/aap.2017.38.4069","article-title":"Fluticasone propionate and fluticasone propionate\/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma","volume":"38","author":"Sher","year":"2017","journal-title":"Allergy Asthma Proc."},{"issue":"5","key":"10.1016\/j.rmed.2022.106993_bib60","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.rmed.2010.11.011","article-title":"Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler","volume":"105","author":"Bodzenta-Lukaszyk","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2022.106993_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pupt.2015.10.001","article-title":"An evaluation of comparative treatment effects with high and low dose fluticasone propionate\/formoterol combination in asthma","volume":"35","author":"Dissanayake","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.rmed.2022.106993_bib62","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3109\/02770903.2012.719253","article-title":"Fluticasone\/formoterol combination therapy versus budesonide\/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety","volume":"49","author":"Bodzenta-Lukaszyk","year":"2012","journal-title":"J. Asthma"},{"issue":"8","key":"10.1016\/j.rmed.2022.106993_bib63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1055\/s-0033-1344349","article-title":"Budesonide\/formoterol maintenance and reliever therapy versus free-combination therapy for asthma: a real-life study","volume":"67","author":"Kardos","year":"2013","journal-title":"Pneumologie"},{"issue":"2","key":"10.1016\/j.rmed.2022.106993_bib64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-2600(14)70266-8","article-title":"Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial","volume":"3","author":"Papi","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2022.106993_bib65","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1183\/09031936.00020310","article-title":"Study Investigators. Mometasone furoate\/formoterol reduces asthma deteriorations and improves lung function","volume":"39","author":"Meltzer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2022.106993_bib66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2500\/aap.2010.31.3364","article-title":"P04334 Study Investigators. Twenty-six-week efficacy and safety study of mometasone furoate\/formoterol 200\/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids","volume":"31","author":"Nathan","year":"2010","journal-title":"Allergy Asthma Proc."},{"issue":"4","key":"10.1016\/j.rmed.2022.106993_bib67","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2500\/aap.2010.31.3381","article-title":"Study Investigators of P04431. Twelve-week efficacy and safety study of mometasone furoate\/formoterol 200\/10 microg and 400\/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids","volume":"31","author":"Weinstein","year":"2010","journal-title":"Allergy Asthma Proc."},{"issue":"5","key":"10.1016\/j.rmed.2022.106993_bib68","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1081-1206(10)60284-0","article-title":"Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler","volume":"101","author":"Chervinsky","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2022.106993_bib69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2022.106993_bib70","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00625-2020","article-title":"SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis","volume":"56","author":"Rogliani","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.106993_bib71","doi-asserted-by":"crossref","first-page":"g3009","DOI":"10.1136\/bmj.g3009","article-title":"Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis","volume":"348","author":"Loymans","year":"2014","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.rmed.2022.106993_bib72","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.2018.2769","article-title":"Association of inhaled corticosteroids and long-acting \u03b2-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2022.106993_bib74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.anai.2019.04.018","article-title":"Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: a Gaining Optimal Asthma Control (GOAL) study reanalysis","volume":"123","author":"Bateman","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2022.106993_bib75","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s12325-022-02092-7","article-title":"New versus Old: the impact of changing patterns of inhaled corticosteroid prescribing and dosing regimens in asthma management","volume":"39","author":"Singh","year":"2022","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.rmed.2022.106993_bib76","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.rmed.2004.04.001","article-title":"The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma","volume":"98","author":"Carranza Rosenzweig","year":"2004","journal-title":"Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112200258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112200258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:12:20Z","timestamp":1730488340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112200258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"alternative-id":["S095461112200258X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2022.106993","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of inhaled fluticasone propionate\/salmeterol on health-related quality of life in asthma: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2022.106993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106993"}}